Avadomide

• Description :

  Avadomide is an orally active cereblon modulator. Avadomide modulates cereblon E3 ligase activity, inhibits NF-κB pathway, arrests the cell cycle at G1 phase, and thus induces apoptosis in cancer cell PDAC. Avadomide exhibits potent antitumor and immunomodulatory activities[1][2][3].

• Product Name Alternative :

  CC 122

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Apoptosis; E1/E2/E3 Enzyme; Molecular Glues; NF-κB

• Type :

  Reference compound

• Related Pathways :

  Apoptosis; Metabolic Enzyme/Protease; NF-κB; PROTAC

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer; Inflammation/Immunology

• Assay Protocol :

  https://www.medchemexpress.com/CC122.html

• Purity :

  99.56

• Solubility :

  DMSO : 33.33 mg/mL (ultrasonic)

• Smiles :

  O=C(C(N1C(C)=NC2=C(C(N)=CC=C2)C1=O)CC3)NC3=O

• Molecular Formula :

  C14H14N4O3

• Molecular Weight :

  286.29

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Hagner, P.R.et al.CC-122, a pleiotropic pathway modifier, mimics an IFN response and has antitumor activity in DLBCL.Blood.Aug 6;126 (6) :779-89.|[2]Rasco DW, et al. A First-in-Human Study of Novel Cereblon Modulator Avadomide (CC-122) in Advanced Malignancies. Clin Cancer Res. 2019 Jan 1;25 (1) :90-98.|[3]Nishi H, et al., Anti-tumor effect of avadomide in gemcitabine-resistant pancreatic ductal adenocarcinoma. Cancer Chemother Pharmacol. 2023 Oct;92 (4) :303-314.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 2

• CAS Number :

  [1015474-32-4]